Compare SNGX & DTST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNGX | DTST |
|---|---|---|
| Founded | 1987 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 7.2M |
| IPO Year | 2006 | 2012 |
| Metric | SNGX | DTST |
|---|---|---|
| Price | $0.34 | $2.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | ★ $1.38 | N/A |
| AVG Volume (30 Days) | 102.4K | ★ 289.0K |
| Earning Date | 11-06-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.03 | ★ 3671.43 |
| EPS | ★ N/A | N/A |
| Revenue | $119,371.00 | ★ $1,382,929.00 |
| Revenue This Year | N/A | $8.47 |
| Revenue Next Year | N/A | $20.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.32 | $2.39 |
| 52 Week High | $3.39 | $5.15 |
| Indicator | SNGX | DTST |
|---|---|---|
| Relative Strength Index (RSI) | 35.83 | 40.67 |
| Support Level | $0.32 | N/A |
| Resistance Level | $0.82 | $3.70 |
| Average True Range (ATR) | 0.02 | 0.32 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 26.22 | 14.93 |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc and corporate segment. It generates maximum revenue from the Nexxis Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.